Table 1.
Metabolite | Source | Pharmacological activity | R&D stage |
---|---|---|---|
Ecteinascidin 743 (YondelisTM) | Ecteinascidia turbinate (Sea squirt) | Anticancer | Market |
Cephalosporine | Cephalosporium acremonium (Fungi) | Antibiotic | Market |
Bengamide derivative (LAF389) | Jaspis sp. (Sponge) | Anticancer | Phase I |
Hemiasterlin derivative (HTI-286) | Cymbastella sp. (Sponge) | Anticancer | Phase I |
Dehydrodidemnine B (AplidineTM) | Aplidium albicans (Tunicate) | Anticancer | Phase II |
Dolastatin 10 | Dolabella auricularia (Mollusc and Cyanobacteria) | Anticancer | Phase II |
Kahalalide F | Elysia rufescens (Sea slug) | Antitumor | Phase II |
Bryostatin 1 | Bugula neritina (Bryozoan) | Anticancer | Phase III |
Diazonamide | Diazona angulata (Tunicate) | Anticancer | Preclinical |
Thiocoraline | Mi Cromonospora marina (Bacteria) | Anticancer | Preclinical |
Vitilevuamide | Didemnum cucliferum and Polysyncraton lithrostrotum (Tunicates) | Anticancer | Preclinical |